The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms
Abstract
Since the discovery of the JAK2V617F tyrosine kinase‐activating mutation several genes have been found mutated in nonchronic myeloid leukemia (CML) myeloproliferative neoplasms (MPNs), which mainly comprise three subtypes of “classic” MPNs; polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). We searched for mutations in ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 genes in 149 non‐CML MPNs, including 127 “classic” MPNs cases. JAK2 was mutated in 100% PV, 66% ET and 68% MF. We found a high incidence of ASXL1 mutation in MF patients (20%) and a low incidence in PV (7%) and ET (4%) patients. Mutations in the other genes were rare (CBL, DNMT3A, IDH2, MPL, SF3B1, SUZ12, NF1) or absent (IDH1). © 2012 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139
Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-401 · Cited by 171
Self-citationMutation in TET2 in Myeloid Cancers
(2009) · New England Journal of Medicine · doi:10.1056/nejmc091348 · Cited by 66
Cited by
Xist RNA Is a Potent Suppressor of Hematologic Cancer in Mice
Yildirim, E., Kirby, J. E., Brown, D. E., Mercier, F. E., Sadreyev, R. I., Scadden, D. T., & Lee, J. T. (2013) · Cell · doi:10.1016/j.cell.2013.01.034 · Cited by 522
Crystal Structure of TET2-DNA Complex: Insight into TET-Mediated 5mC Oxidation
Hu, L., Li, Z., Cheng, J., Rao, Q., Gong, W., Liu, M., Shi, Y. G., Zhu, J., Wang, P., & Xu, Y. (2013) · Cell · doi:10.1016/j.cell.2013.11.020 · Cited by 450
Gelsi-Boyer, V., Brecqueville, M., Devillier, R., Murati, A., Mozziconacci, M.-J., & Birnbaum, D. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-12 · Cited by 278
Self-citationTefferi, A., & Barbui, T. (2015) · American Journal of Hematology · doi:10.1002/ajh.23895 · Cited by 270
Myeloid malignancies: mutations, models and management
Murati, A., Brecqueville, M., Devillier, R., Mozziconacci, M.-J., Gelsi-Boyer, V., & Birnbaum, D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-304 · Cited by 139
Self-citation
Metadata
- Authors
- Brecqueville, M., Rey, J., Bertucci, F., Coppin, E., Finetti, P., Carbuccia, N., Cervera, N., Gelsi‐Boyer, V., Arnoulet, C., Gisserot, O., Verrot, D., Slama, B., Vey, N., Mozziconacci, M., Birnbaum, D., & Murati, A.
- Venue
- Genes, Chromosomes and Cancer
- Publisher
- Wiley
- Published
- 2012-04-09
- Volume
- 51
- Issue
- 8
- Pages
- 743-755
- ISSN
- 1045-2257 (ISSN-L)
- 1098-2264
- OpenAlex
- W2093657334
- Cited by
- 158
- References
- 7
- FWCI
- 9.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.